Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 16, 2011 Brian Orelli	Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly.
Chemistry World December 20, 2013 Patrick Walter	AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture.
The Motley Fool May 26, 2011 Brian Orelli	Amylin Scores First in Court But it is still early innings.
The Motley Fool November 8, 2011 Tim Beyers	Amylin Pharmaceuticals Shares Plummeted: What You Need to Know Is this meaningful, or just another movement for Amylin Pharmaceuticals?
The Motley Fool July 22, 2010 Brian Orelli	It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead.
The Motley Fool November 9, 2011 Brian Orelli	Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it
The Motley Fool October 21, 2011 Brian Orelli	Full of News, but Worth a 15% Gain? Amylin serves up an appetizer.
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
The Motley Fool April 20, 2010 Brian Orelli	Drug Sales Down! Should We Celebrate? Amylin won't have completed results for a trial comparing Bydureon to Victoza until next year. But until that data is in, it might not be as easy to get the patients back as Amylin is making it out to be.
The Motley Fool March 15, 2010 Brian Orelli	FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it.
The Motley Fool July 22, 2008 Brian Orelli	Anemic Amylin's Signs of Recovery Sales of Amylin Pharmaceuticals' diabetes drug Byetta have slowed over the last few quarters, but the company seems to be turning things around.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
The Motley Fool October 2, 2009 Brian Orelli	Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug.
The Motley Fool March 3, 2011 Brian Orelli	Amylin Comes Up Snake Eyes Amylin Pharmaceuticals and partners Eli Lilly and Alkermes announced results of their head-to-head clinical trial comparing Bydureon with Novo Nordisk's diabetes drug Victoza.
The Motley Fool September 9, 2008 Brian Orelli	Drug Duo Combines Its Way Toward an Approval Bristol-Myers and AstraZeneca are trying to get their diabetes drug approved as a combination treatment.
The Motley Fool March 3, 2011 Brian D. Pacampara	Amylin Pharmaceuticals Shares Plunged: What You Need to Know Shares of Amylin Pharmaceuticals plummeted more than 20% Thursday after its type 2 diabetes drug Bydureon failed to meet primary endpoints in a 26-week study.
The Motley Fool June 16, 2010 Brian Orelli	A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market.
The Motley Fool August 23, 2005 Stephen D. Simpson	A Cure for Amylin's Stock? Shares moved up after promising results from a diabetes-drug test. But will the gains last?
The Motley Fool March 17, 2005 Stephen D. Simpson	Patience Rewarded at Last Amylin's battle to get Symlin approved was long and difficult, but success will have its rewards. Should investors take a shot?
The Motley Fool July 21, 2006 Stephen D. Simpson	Lilly Wilts Neither the valuation nor the pipeline of this pharma makes for a compelling investment case.
The Motley Fool December 7, 2007 Brian Orelli	Amylin's Temporarily Worthless Label Expansion Amylin releases label expansion data that won't be useful for a few years. Investors, take note.
The Motley Fool November 3, 2009 Brian Orelli	Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend.
The Motley Fool October 19, 2006 Brian Lawler	Amylin's One-Drug Wonder Unfortunately, with research and development costs growing to $54 million from $33 million last year, Amylin is still a few quarters away from profitability. Diabetes drug Byetta is set to boost Amylin's sales. Investors, take note.
The Motley Fool June 24, 2008 Brian Orelli	A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly.
The Motley Fool November 24, 2006 Brian Lawler	Amylin Gets Past the Formalities Following a formal approval from the EU for Byetta, Amylin can get down to business. Investors, take note.
The Motley Fool July 8, 2011 Brian Orelli	Let's Just Hope For No More FDA Surprises Despite the government's worries, Bydureon doesn't cause heart issues.
The Motley Fool February 20, 2009 Brian Orelli	The Skinny on Diabetes Drugs The goal of diabetes drugs is to get the patient's blood glucose levels under control, but one class of drugs, called GLP1 agonists, have a nice side effect: weight loss. Which pharma companies can benefit?
The Motley Fool July 21, 2005 Stephen D. Simpson	Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well.
The Motley Fool April 18, 2005 Stephen D. Simpson	Is Lilly About to Bloom? Two new diabetes products could add a little punch to this drug-maker's top line. Lilly shares are not really "cheap" these days, but there's a lot to like about a company with no legal overhang, several new drugs, and a decent dividend yield.
The Motley Fool April 15, 2011 Luke Timmerman	Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe?
The Motley Fool May 19, 2008 Brian Orelli	What Will Icahn Do With Amylin? Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals, and stockholders must be wondering about his motivation for the purchase.
The Motley Fool January 27, 2011 Brian Orelli	Amylin Timeline Shortened -- Maybe Revenue down 6% year over year. Prescriptions of the company's top-selling drug, Byetta, down 5.9% quarter over quarter. Amylin Pharmaceuticals' fourth quarter wasn't pretty.
The Motley Fool June 29, 2011 Brian Orelli	Doubling Up in Biotech Lilly hits multiple targets with one drug.
The Motley Fool November 8, 2011 David Williamson	Biotech Pops, Drops, and Break-Ups Highlighting the day's health-care stories critical to investors.
The Motley Fool December 9, 2008 Brian Orelli	FDA Dashes Amylin Investors' Hopes Shareholders are still waiting to hear how much longer it'll be before Amylin and Eli Lilly can submit the marketing application for the once-weekly version of diabetes drug Byetta.
The Motley Fool July 22, 2009 Brian Orelli	The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough?
The Motley Fool November 30, 2007 Brian Orelli	Analyzing Amylin Amylin Pharmaceuticals holds its R&D day to update investors on the marketing strategy of its two diabetes products, as well as the development of its pipeline.
The Motley Fool January 31, 2007 Brian Lawler	No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note.
The Motley Fool September 20, 2010 Brian Orelli	Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time.
The Motley Fool October 20, 2010 Brian Orelli	There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon.
BusinessWeek January 9, 2006 Arlene Weintraub	Bucking The Odds at Amylin With Ginger Graham at the helm, Amylin Pharmaceuticals has two approved diabetes drugs.
The Motley Fool May 31, 2011 Brian Orelli	Pay Attention, Biotech Investors Competitors and partners can't be ignored.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool April 17, 2009 Brian Orelli	Cost-Cutting? Check. Increased Sales? Hmm ... Amylin has half the equation. Now it needs the other half.
The Motley Fool November 18, 2008 Brian Orelli	Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere.
The Motley Fool October 2, 2007 Brian Orelli	Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note.
The Motley Fool January 26, 2006 Stephen D. Simpson	Will New Drugs Gild Lilly? Although Lilly's late-stage pipeline is weak, newer drugs should still be able to grow. Investors, this is still a mediocre investment option.
Chemistry World April 4, 2013 Phillip Broadwith	Amylin headquarters to close with further job losses Bristol-Myers Squibb has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin.
The Motley Fool October 18, 2007 Brian Orelli	Amylin: Waiting on the Future Research and development costs drag down the drug developer's bottom line. Investors, take note.
The Motley Fool January 29, 2008 Brian Orelli	No Weight Loss at Amylin Bulging costs related to its diabetes drug Byetta keep the drugmaker from showing a profit this quarter.